Medico Remedies Ltd Upgraded to Hold by MarketsMOJO on Improved Fundamentals and Technicals

Technical Trends Show Signs of Stabilisation

The primary catalyst for the upgrade stems from a shift in the technical grade from bearish to mildly bearish. While the stock’s weekly and monthly MACD indicators remain bearish, there are encouraging signs in other technical parameters. The weekly Bollinger Bands have turned bullish, suggesting increased price momentum in the short term, although the monthly Bollinger Bands remain mildly bearish, indicating some caution over a longer horizon.

Moving averages on a daily basis continue to show a mildly bearish trend, but the KST (Know Sure Thing) indicator has improved to mildly bullish on a weekly basis, signalling potential upward momentum. Dow Theory assessments remain mildly bearish on both weekly and monthly timeframes, while the On-Balance Volume (OBV) is mildly bearish weekly but shows no clear trend monthly. Overall, these mixed signals suggest the stock is stabilising technically, warranting a more neutral stance rather than a sell recommendation.

Price action supports this view, with the stock closing at ₹42.98 on 28 July 2026, up 5.73% from the previous close of ₹40.65. The intraday range was ₹40.20 to ₹44.31, showing increased volatility but also buying interest. The 52-week high stands at ₹56.99, while the low is ₹31.00, placing the current price closer to the lower end but with room for recovery.

Financial Trend: Robust Quarterly Performance and Debt Management

Medico Remedies has demonstrated positive financial momentum in the latest quarter (Q4 FY25-26), which has contributed significantly to the rating upgrade. Net sales surged by 37.55% to ₹56.81 crores, marking the fifth consecutive quarter of positive results. Profitability metrics also hit new highs, with PBDIT reaching ₹7.15 crores and PBT (excluding other income) at ₹5.45 crores.

The company’s return on capital employed (ROCE) stands at a healthy 15.04%, reflecting efficient management and utilisation of capital resources. This is complemented by a low Debt to EBITDA ratio of 0.82 times, indicating strong debt servicing ability and a conservative capital structure. Such financial discipline reduces risk and supports sustainable growth prospects.

However, long-term growth remains a concern, with net sales growing at an annualised rate of only 14.28% over the past five years. This slower pace contrasts with the more recent quarterly acceleration, suggesting that while the company is improving, investors should remain cautious about sustained growth potential.

Valuation: Attractive Discount Amid Fair Metrics

Valuation metrics for Medico Remedies indicate a fair but discounted position relative to its peers. The company’s Enterprise Value to Capital Employed ratio is 4.9, which is reasonable given its ROCE of 15.8%. The stock trades at a discount compared to the average historical valuations of its sector peers, offering a potential value opportunity for investors willing to accept moderate risk.

Over the past year, the stock has delivered a 7.45% return, outperforming the Sensex which declined by 5.10% in the same period. Profit growth has been robust at 30%, resulting in a PEG ratio of 0.9, which suggests the stock is reasonably priced relative to its earnings growth. This combination of fair valuation and improving fundamentals supports the Hold rating, signalling neither a strong buy nor a sell.

Quality Assessment: Management Efficiency and Shareholder Structure

Medico Remedies benefits from high management efficiency, as evidenced by its consistent quarterly performance and strong ROCE. The company’s promoter group remains the majority shareholder, providing stability and alignment of interests with minority investors. This ownership structure often favours long-term strategic planning and disciplined capital allocation.

Despite these positives, the company’s micro-cap status and relatively modest market capitalisation imply higher volatility and risk compared to larger pharmaceutical peers. Investors should weigh these factors carefully when considering exposure to Medico Remedies.

Stock Performance in Context

Examining Medico Remedies’ returns relative to the broader market provides additional insight. The stock outperformed the Sensex over the past week and month, with returns of 12.81% and 6.54% respectively, compared to the Sensex’s negative returns of -0.91% and -0.43%. Year-to-date, however, the stock has declined by 14.99%, slightly worse than the Sensex’s -9.92% performance.

Longer-term returns are mixed: a 7.45% gain over one year contrasts with a significant 46.28% decline over three years, while the five-year return is an impressive 330.34%, far exceeding the Sensex’s 46.38%. This volatility underscores the stock’s micro-cap nature and the importance of monitoring ongoing performance trends.

Conclusion: A Cautious Upgrade Reflecting Mixed Signals

The upgrade of Medico Remedies Ltd from Sell to Hold reflects a balanced assessment of its current position. Improved technical indicators, strong recent financial results, and reasonable valuation metrics support a more positive outlook. However, concerns remain regarding long-term growth rates and the inherent risks of a micro-cap pharmaceutical stock.

Investors are advised to consider Medico Remedies as a potential portfolio holding for those seeking exposure to the Pharmaceuticals & Biotechnology sector with moderate risk tolerance. Continued monitoring of quarterly results and technical trends will be essential to reassess the stock’s trajectory and potential for further upgrades or downgrades.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today